In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.
作者信息
Lavie Carl J
机构信息
John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA.
出版信息
Mayo Clin Proc. 2021 May;96(5):1367-1368. doi: 10.1016/j.mayocp.2021.03.002. Epub 2021 Mar 5.
Abstract
摘要
相似文献
1
In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.回复——法莫替丁的使用与新冠肺炎患者重症病程风险：一项荟萃分析。
Mayo Clin Proc. 2021 May;96(5):1367-1368. doi: 10.1016/j.mayocp.2021.03.002. Epub 2021 Mar 5.
2
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.法莫替丁的使用与 COVID-19 患者重症病程风险：一项荟萃分析
Mayo Clin Proc. 2021 May;96(5):1365-1367. doi: 10.1016/j.mayocp.2021.03.001. Epub 2021 Mar 5.
3
Famotidine and Mortality in Coronavirus Disease 2019.法莫替丁与2019冠状病毒病死亡率
Gastroenterology. 2021 Jul;161(1):361-362. doi: 10.1053/j.gastro.2020.12.045. Epub 2020 Dec 31.
4
Histamine receptors and COVID-19.组胺受体与 COVID-19。
Inflamm Res. 2021 Jan;70(1):67-75. doi: 10.1007/s00011-020-01422-1. Epub 2020 Nov 18.
5
Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?法莫替丁与住院的新冠病毒肺炎患者：益处是真的吗？
Am J Gastroenterol. 2021 Jul 1;116(7):1561. doi: 10.14309/ajg.0000000000001217.
6
Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.法莫替丁使用与新型冠状病毒肺炎患者临床结局之间的关联：现有证据评估
Am J Gastroenterol. 2021 Apr;116(4):848-849. doi: 10.14309/ajg.0000000000001008.
7
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.法莫替丁能否降低新冠病毒肺炎患者进展为重症疾病、死亡及插管的风险？一项系统评价与Meta分析
Dig Dis Sci. 2021 Nov;66(11):3929-3937. doi: 10.1007/s10620-021-06872-z. Epub 2021 Feb 24.
8
Famotidine and Coronavirus Disease 2019.法莫替丁与2019冠状病毒病
Gastroenterology. 2021 Jul;161(1):360-361. doi: 10.1053/j.gastro.2020.12.044. Epub 2020 Dec 30.
9
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.法莫替丁在非住院 COVID-19 患者中的应用及定量症状跟踪：一项病例系列研究。
Gut. 2020 Sep;69(9):1592-1597. doi: 10.1136/gutjnl-2020-321852. Epub 2020 Jun 4.
10
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.法莫替丁治疗新冠病毒病的临床疗效无证据：一项系统评价和荟萃分析。
J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.022. Epub 2022 Dec 1.
引用本文的文献
1
Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials.冠心病患者使用秋水仙碱：随机试验的系统评价与荟萃分析
J Am Heart Assoc. 2021 Aug 17;10(16):e021198. doi: 10.1161/JAHA.121.021198. Epub 2021 Aug 7.
本文引用的文献
1
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.痛风的心血管疾病药物治疗：药物疗效和预后的综述。
Am J Cardiovasc Drugs. 2021 Sep;21(5):499-512. doi: 10.1007/s40256-020-00459-1. Epub 2020 Dec 28.
2
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.新冠肺炎大流行期间的扩大准入计划、同情用药和紧急使用授权。
Drug Discov Today. 2021 Feb;26(2):593-603. doi: 10.1016/j.drudis.2020.11.025. Epub 2020 Nov 27.
3
Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19".作者对弗拉查蒂斯等人《COVID-19的药物免疫调节疗法》的回复
Drugs. 2020 Sep;80(14):1501-1503. doi: 10.1007/s40265-020-01396-8.
4
Famotidine Against SARS-CoV2: A Hope or Hype?法莫替丁对新型冠状病毒2：希望还是炒作？
Mayo Clin Proc. 2020 Aug;95(8):1797-1799. doi: 10.1016/j.mayocp.2020.05.027. Epub 2020 Jun 6.
5
Pharmaco-Immunomodulatory Therapy in COVID-19.COVID-19 的药物免疫调节治疗。
Drugs. 2020 Sep;80(13):1267-1292. doi: 10.1007/s40265-020-01367-z.
6
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.秋水仙碱对比标准治疗对 COVID-19 住院患者心脏和炎症生物标志物及临床结局的影响：GRECCO-19 随机临床试验。
JAMA Netw Open. 2020 Jun 1;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136.
7
Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.营养保健品有潜力增强对包括流感病毒和冠状病毒在内的RNA病毒的1型干扰素反应。
Prog Cardiovasc Dis. 2020 May-Jun;63(3):383-385. doi: 10.1016/j.pcad.2020.02.007. Epub 2020 Feb 12.
Zotero 插件